| Date | Title | Description |
| 15.09.2024 | Rexel: Rexel Board of Directors rejects an unsolicited preliminary proposal from QXO | Rexel Board of Directors rejects an unsolicited preliminary proposal from QXO
Rexel confirms it has received earlier this week an unsolicited, non-binding preliminary proposal from QXO regarding a potential acquisition of Rexel at an indica... |
| 13.09.2024 | Endeavour Achieves Commercial Production at BIOX Expansion and Lafigué Growth Projects | ENDEAVOUR ACHIEVES COMMERCIAL PRODUCTION AT BIOX EXPANSION AND LAFIGUÉ GROWTH PROJECTS
HIGHLIGHTS:
• Commercial production achieved on budget and on schedule at the Sabodala-Massawa BIOX Expansion and the Lafigué mine on 1 August 2024
• Org... |
| 13.09.2024 | Roc Oil Company Pty Limited announces a recommended cash offer to the shareholders of Tethys Oil AB | Roc Oil Company Pty Limited announces a recommended cash offer to the shareholders of Tethys Oil AB
Fri, Sep 13, 2024 09:01 CET Report this content
THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, BELARUS, CA... |
| 13.09.2024 | Endeavour Achieves Commercial Production at BIOX Expansion and Lafigué Growth Projects | ENDEAVOUR ACHIEVES COMMERCIAL PRODUCTION AT BIOX EXPANSION AND LAFIGUÉ GROWTH PROJECTS
HIGHLIGHTS:
• Commercial production achieved on budget and on schedule at the Sabodala-Massawa BIOX Expansion and the Lafigué mine on 1 August 2024
• Org... |
| 10.09.2024 | SMCP - New partner in Indonesia and in the Philippines | Press release - Paris, September 9th, 2024
After India, SMCP carries on its international expansion and enters Indonesia and the Philippines
SMCP, parent company of the brands Sandro, Maje, Claudie Pierlot and Fursac, is delighted to announ... |
| 09.09.2024 | Planisware recognized as a Leader in 2024 Gartner® Magic Quadrant™ for Adaptive Project Management & Reporting report | Planisware recognized as a Leader in 2024 Gartner® Magic Quadrant™ for Adaptive Project Management & Reporting report
Paris, France, September 9, 2024 – Planisware, a leading B2B provider of SaaS in the rapidly growing Project Economy m... |
| 30.08.2024 | Paramount Global's Path Forward: The End of the Bidding War | In the fast-paced world of media, change is the only constant. Paramount Global, a titan in the entertainment industry, has recently navigated through a stormy bidding war. The dust has settled, and the horizon is clearer now. Edgar Bronfma... |
| 30.08.2024 | HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA... |
| 30.08.2024 | HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA... |
| 26.08.2024 | PARAMOUNT GLOBAL'S SPECIAL COMMITTEE ANNOUNCES END OF "GO-SHOP" PROCESS | NEW YORK, Aug. 26, 2024 /PRNewswire/ -- The Special Committee of the Board of Directors (the "Special Committee") of Paramount Global (NASDAQ: PARA, PARAA) ("Paramount" or "the Company") today confirmed that it... |
| 21.08.2024 | PARAMOUNT GLOBAL'S SPECIAL COMMITTEE ANNOUNCES RECEIPT OF ACQUISITION PROPOSAL AND 15-DAY EXTENSION OF "GO SHOP" PERIOD TO CONTINUE ENGAGEMENT | NEW YORK, Aug. 21, 2024 /PRNewswire/ -- The Special Committee of the Board of Directors (the "Special Committee") of Paramount Global (NASDAQ: PARA, PARAA) ("Paramount" or "the Company") today announced the rec... |
| 21.08.2024 | HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion lead... |
| 05.08.2024 | SMCP - Liquidity contract | Press release - Paris, August 5th, 2024
Termination and implementation of a liquidity contract with Rothschild Martin Maurel
On August 2nd, 2024, SMCP terminated the liquidity contract with BNP Paribas Arbitrage since November 28th, 2017.
O... |
| 31.07.2024 | HUTCHMED Reports 2024 Interim Results and Provides Business Updates | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, ... |
| 31.07.2024 | Inventiva Reports Preliminary 2024 First-Half Financial Information¹ | Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023.
On July 18, 2024,... |
| 30.07.2024 | Rexel: Q2 sales & H1 2024 results | Q2 SALES & H1 2024 RESULTS
Sequential organic sales improvement between Q1 and Q2
Resilient profitability and record FCF generation in H1 24, supported by strong discipline and self-help plans
2024 outlook confirmed - in the lower end o... |
| 30.07.2024 | Rexel’s First Half 2024 Financial Report Made Available | REXEL’S FIRST HALF 2024 FINANCIAL REPORT
MADE AVAILABLE
Rexel’s first-half 2024 financial report was filed on July 30, 2024 with the French Autorité des marches financiers (AMF).
It is also made available on Rexel’s corporate website (https... |
| 30.07.2024 | Rexel: Ventes du T2 et résultats du S1 2024 | VENTES DU T2 ET RESULTATS DU S1 2024
Amélioration séquentielle de l'évolution organique des ventes entre T1 et T2
Résilience de la profitabilité et génération de FCF record au S1 24, soutenues par une discipline rigoureuse et nos plans d'ac... |
| 30.07.2024 | Rexel: Q2 sales & H1 2024 results | Q2 SALES & H1 2024 RESULTS
Sequential organic sales improvement between Q1 and Q2
Resilient profitability and record FCF generation in H1 24, supported by strong discipline and self-help plans
2024 outlook confirmed - in the lower end o... |
| 30.07.2024 | Planisware: H1 2024 results fully in line with FY planned trajectory | H1 2024 results fully in line with FY planned trajectory H1 2024 revenue growth of +19.6% in constant currencies, reaching € 86.6 millionAdjusted EBITDA margin representing 33.5% of revenueStrong cash conversion representing 127% of adjuste... |
| 29.07.2024 | Rexel: Biannual update of the liquidity agreement | BIANNUAL UPDATE OF THE LIQUIDITY AGREEMENT BETWEEN REXEL AND NATIXIS-ODDO BHF
Under the terms of the liquidity and market surveillance agreement with NATIXIS ODDO BHF covering Rexel shares, at June 30, 2024 the following resources were incl... |
| 27.07.2024 | The New Landscape of Mergers and Leadership Changes in Global Industries | In the fast-paced world of business, mergers and leadership changes are like tectonic plates shifting beneath our feet. They reshape the landscape, creating new opportunities and challenges. Recently, two significant events have captured at... |
| 27.07.2024 | Mergers and Market Moves: Hollysys and Portage Point Partners Shape the Future | In the fast-paced world of finance, mergers and acquisitions often signal significant shifts. Recently, two notable events have captured attention: Hollysys Automation Technologies Ltd.'s merger with Ascendent Capital Partners and the addit... |
| 26.07.2024 | Hollysys Announces Completion of Merger Transaction with Ascendent Capital Partners | • Requests trading of its shares be suspended as of close of trading July 25, 2024
BEIJING, July 26, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") and Ascendent C... |
| 25.07.2024 | SMCP - Press Release - 2024 H1 Results | H1 2024 Results
Press release - Paris, July 25th, 2024
Resilient sales excluding China
Continued financial discipline and execution of the action plan H1 2024 Sales at €585m, decreasing by -3.6% on an organic0F0F1 basis vs. H1 2023 Sales at... |
| 25.07.2024 | Hollysys Announces Completion of Merger Transaction with Ascendent Capital Partners | • Requests trading of its shares be suspended as of close of trading July 25, 2024
BEIJING, July 25, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") and Ascendent C... |
| 25.07.2024 | Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor | Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1
This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indi... |
| 23.07.2024 | Vale Base Metals appoints Shaun Usmar as new Chief Executive Officer | TORONTO, July 23, 2024 /PRNewswire/ -- Vale Base Metals Ltd. ("VBM"), the holding entity for Vale's energy transition metals business, today announces the appointment of Shaun Usmar as Chief Executive Officer. Mr. Usmar will assum... |
| 19.07.2024 | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecu... |
| 18.07.2024 | Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros | Certificats de royalties souscrits par Samsara BioCapital et des actionnaires existants BVF Partners, NEA, Sofinnova et Yiheng.
Royalties de 3 % sur les ventes nettes futures du lanifibranor aux Etats Unis, dans l’Union européenne et au Roy... |
| 18.07.2024 | Inventiva announces a €20.1 million issuance of royalty certificates | Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).
Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United ... |
| 18.07.2024 | Hollysys Announces Expected Completion Date of Merger Transaction with Ascendent Capital Partners | BEIJING, July 18, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced that it expects to complete its merger transaction with a buyer controlled by Asce... |
| 18.07.2024 | Inventiva announces a €20.1 million issuance of royalty certificates | Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).
Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United ... |
| 18.07.2024 | Hollysys Announces Expected Completion Date of Merger Transaction with Ascendent Capital Partners | BEIJING, July 18, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced that it expects to complete its merger transaction with a buyer controlled by Asce... |
| 11.07.2024 | Though Headwinds Mount, ALM Pacesetter Research Finds that ESG's Social Component Continues to Figure in Client Business Strategies | ALM
A new report on the "S" of ESG finds that Innovators are helping clients confront the complexities of ESG in business, helping address risk while also supporting fundamental value creation and long-term business strategy
NEW Y... |
| 07.07.2024 | PARAMOUNT GLOBAL'S SPECIAL COMMITTEE UNANIMOUSLY APPROVES MERGER WITH SKYDANCE MEDIA | NEW YORK, July 7, 2024 /PRNewswire/ -- The Special Committee of the Board of Directors (the "Special Committee") of Paramount Global (NASDAQ: PARA, PARAA) ("Paramount" or "the Company") today confirmed that it ... |
| 05.07.2024 | Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr | Le recrutement dans l'essai clinique de phase III NATiV3 se poursuit dans les deux cohortes avec plus de 80% du nombre ciblé de patients recrutés dans la cohorte principale et 100% dans la cohorte exploratoire de NATiV3.
L'analyse des carac... |
| 05.07.2024 | Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position | Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.
Analysis of the baseline characteristics of all patien... |
| 05.07.2024 | Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position | Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.
Analysis of the baseline characteristics of all patien... |
| 04.07.2024 | Rexel émet avec succès son premier Schuldschein pour 200 millions d’euros | Rexel émet avec succès son premier Schuldschein pour 200 millions d’euros
Rexel annonce aujourd’hui le succès de son premier placement privé de type Schuldschein, d’un montant de 200 M€, réparti en deux maturités de 3 et 5 ans.
Initialement... |
| 04.07.2024 | Rexel successfully issued its first Schuldschein for 200 million euros | Rexel successfully issued its first Schuldschein for 200 million euros
Rexel announces today the success of its first Schuldschein private placement, totaling 200 million euros, with two tranches of three and five years.
Initially planned a... |
| 04.07.2024 | HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of a... |
| 02.07.2024 | Hollysys Announces Completion of Regulatory Review of Merger Transaction | BEIJING, July 2, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced that it has been informed by Ascendent Capital Partners ("Ascendent") tha... |
| 02.07.2024 | Hollysys Announces Completion of Regulatory Review of Merger Transaction | BEIJING, July 2, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced that it has been informed by Ascendent Capital Partners ("Ascendent") tha... |
| 24.06.2024 | Africa Oil Announces Agreement To Consolidate the Remaining 50% Interest in Prime | Africa Oil Announces Agreement To Consolidate the Remaining 50% Interest in Prime
Mon, Jun 24, 2024 08:00 CET Report this content
Transaction consolidates ownership in core cash generating assets and brings in a new strategically aligned co... |
| 24.06.2024 | Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesd... |
| 21.06.2024 | Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 | Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies... |
| 21.06.2024 | HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda | — Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
— FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer rega... |
| 21.06.2024 | HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda | — Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
— FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer rega... |
| 21.06.2024 | DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024 | Daix, le 21 juin 2024 En application de l'article 241-2 du Règlement Général de l’Autorité des marchés financiers (AMF), le présent descriptif a pour finalité de présenter les objectifs ainsi que les modalités du programme de rachat d’actio... |
| 21.06.2024 | Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 | Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies... |
| 21.06.2024 | Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024 | Daix (France), Long Island City (New York, Etats-Unis), le 21 juin 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées pa... |
| 21.06.2024 | Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 | Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase p... |
| 21.06.2024 | Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 | Daix, 21 June 2024
Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase p... |
| 16.06.2024 | HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology | — Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —
— Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1... |
| 13.06.2024 | Planisware publishes its first Extra-Financial Performance Statement | Planisware publishes its first
Extra-Financial Performance Statement
Paris, France, June 13, 2024 – Planisware, a leading B2B SaaS software provider in the fast-growing Project Economy sector, announces the publication of its first Extra-Fi... |
| 07.06.2024 | "Powering up Rexel" pour atteindre un nouveau palier | « Powering up Rexel » pour atteindre un nouveau palier
Mise à jour de la feuille de route à moyen terme et objectifs financiers réhaussés
présentés lors d’une journée investisseurs
Rexel organise aujourd'hui à partir de 10h15 CEST, une jour... |
| 07.06.2024 | HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in... |
| 07.06.2024 | Powering Up Rexel to the next level | Powering Up Rexel to the next level
Update on medium-term roadmap and upgraded financial targets
presented at Capital Markets Day
Rexel is hosting today from 10.15AM CEST a Capital Markets Day in Paris to present an update on its strategic ... |
| 03.06.2024 | Hollysys Announces Appointment of New Auditor | BEIJING, June 3, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced the appointment of Vocation HK CPA Limited ("Vocation") as its independen... |
| 03.06.2024 | Hollysys Announces Appointment of New Auditor | BEIJING, June 3, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced the appointment of Vocation HK CPA Limited ("Vocation") as its independen... |
| 24.05.2024 | HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by... |
| 22.05.2024 | Hollysys CEO Informs Company of Recent Share Sales | Expects to maintain majority of his holdings in the Company in anticipation of the going private transaction closing
BEIJING, May 22, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the &qu... |
| 17.05.2024 | HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-
(a) the retirement of Mr Simon To from the position as Chai... |
| 17.05.2024 | HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress | HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib,... |
| 16.05.2024 | Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH | The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety... |
| 16.05.2024 | Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH | Le Data Monitoring Committee recommande sur la base d’une revue planifiée des données de sécurité que l’étude clinique de Phase III continue sans modification du protocole actuel.
L’évaluation réalisée par le DMC est basée sur l’examen non ... |
| 15.05.2024 | Africa Oil Announces First Quarter 2024 Results | Africa Oil Announces First Quarter 2024 Results
Wed, May 15, 2024 23:00 CET Report this content
VANCOUVER, BC, May 15, 2024 /CNW/ – (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, “AOC” or the “Company”) is pleased to anno... |
| 02.05.2024 | Endeavour Reports Q1-2024 Results | ENDEAVOUR REPORTS Q1-2024 RESULTS
On track for 2024 guidance • BIOX® Expansion first gold achieved • Lafigué dry commissioning underway
OPERATIONAL AND FINANCIAL HIGHLIGHTS (for continuing operations unless otherwise specified)
Q1-2024 prod... |
| 29.04.2024 | Endeavour Achieves First Gold Pour At Sabodala-Massawa Expansion | First gold delivered in only 2 years · On budget and on schedule · 0 LTIs with over 3.5m man hours worked
ENDEAVOUR ACHIEVES FIRST GOLD POUR AT SABODALA-MASSAWA EXPANSION
First gold delivered in only 2 years · On budget and on schedule · 0 ... |
| 26.04.2024 | HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda | — If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
— Positive opinion based on results from FRESCO-2 Phase III clinic... |
| 23.04.2024 | Boardroom drama at MultiChoice | Imtiaz Patel
Talk about corporate intrigue: just weeks after announcing that its chairman, Imtiaz Patel, would stay on to oversee a possible deal with Groupe Canal+, MultiChoice Group on Tuesday announced Patel’s exit from the role with imm... |
| 21.04.2024 | Australia vs. X: Social Media Platform Challenges Bishop Stabbing Content Takedown | Quincy Jon, Tech Times 21 April 2024, 12:04 pm
Social media platform X stated on Saturday that it will challenge an Australian regulator's demand to remove tweets about a Sydney bishop's stabbing.
CCTV footage showed the crowd holding the 1... |
| 03.04.2024 | Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies fo... |
| 03.04.2024 | Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») | Daix (France), Long Island City (New York, United States), le 3 avril 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules admi... |
| 22.03.2024 | Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results | Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment... |
| 22.03.2024 | Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 | Daix (France), Long Island City (New York, Etats-Unis), le 22 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules adminis... |
| 18.03.2024 | Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D | LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.
Statistical significance was also achieved on several marke... |
| 18.03.2024 | Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de t... | LEGEND a atteint son critère principal d’efficacité en réduisant de manière significative le taux d’hémoglobine HbA1c dans les groupes recevant lanifibranor seul ou en combinaison avec empagliflozine, par rapport au groupe placebo.
Un effet... |
| 14.03.2024 | Nordic Capital to invest in leading digital insurance payments network One Inc to drive continued growth and product innovation | Nordic Capital to invest in leading digital insurance payments network One Inc to drive continued growth and product innovation
Thu, Mar 14, 2024 15:00 CET Report this content
Strategic investment will support One Inc’s mission to digitaliz... |
| 13.03.2024 | Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2 | Daix (France), Long Island City (New York, États-Unis), le 13 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules adminis... |
| 13.03.2024 | Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies f... |
| 28.02.2024 | Nordic Capital makes majority investment in ActiveViam, provider of advanced analytics for financial institutions | Nordic Capital makes majority investment in ActiveViam, provider of advanced analytics for financial institutions
Wed, Feb 28, 2024 13:00 CET Report this content
The investment is made in partnership with ActiveViam’s founders and managemen... |
| 24.02.2024 | Lotus Technology Celebrates Public Listing on Nasdaq | NEW YORK and SINGAPORE, Feb. 24, 2024 /PRNewswire/ -- Lotus Technology Inc. ("Lotus Tech" or the "Company"), a leading global luxury electric vehicle maker, rang today's opening bell at the Nasdaq stock exchange in New Y... |
| 23.02.2024 | Lotus Tech and L Catterton Asia Acquisition Corp Complete Business Combination | NEW YORK and SINGAPORE, Feb. 23, 2024 /PRNewswire/ -- Lotus Technology Inc. ("Lotus Tech" or the "Company"), a leading global luxury electric vehicle maker, and L Catterton Asia Acquisition Corp ("LCAA") (NASDA... |
| 20.02.2024 | Lotus Tech and L Catterton Asia Acquisition Corp Announce Closing of Business Combination | Lotus Tech's American Depositary Shares to Begin Trading on the Nasdaq on February 23, 2024 under Ticker Symbol "LOT"
NEW YORK and SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- Lotus Technology Inc. ("Lotus Tech" or the "... |
| 15.02.2024 | Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3 | Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, contre 12,2 millions d’euros sur la même période en 2022
Trésorerie et équivalents de trésorerie à 26,9 millions d’euros, dépôt à court-terme de 0,01 million2 d’euros et dépôt à... |
| 15.02.2024 | Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 | Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022
Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit at €9.0 million3 as of December 31, 2023, comp... |
| 14.02.2024 | Q4 Sales & fy 2023 Results | Q4 SALES & FY 2023 RESULTS
Record sales, adjusted Ebita margin1 and free cash flow
Upgraded full-year guidance fully achieved, with Ebita in the upper end of the range
Strong free cash flow generation, demonstrating the strength and res... |
| 14.02.2024 | VENTES DU 4ème TRIMESTRE ET RÉSULTATS 2023 | VENTES DU 4ème TRIMESTRE ET RÉSULTATS 2023
Ventes, marge d'EBITA ajusté1 et Free cash flow records
Objectifs annuels réhaussés atteints, avec une marge d'EBITA dans le haut de la fourchette
Forte génération de free cash flow, démontrant la ... |
| 08.02.2024 | Hollysys Announces Shareholder Approval of Merger Agreement with Ascendent | BEIJING, Feb. 8, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced that, at an extraordinary general meeting of shareholders ("EGM") held to... |
| 07.02.2024 | HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in ... |
| 31.01.2024 | Hollysys Recommends Shareholders Vote FOR Ascendent Transaction to Secure Compelling Value | Updated proxy to detail recent engagement with Dazheng
BEIJING, Jan. 31, 2024 /PRNewswire/ -- The Board of Directors of Hollysys Automation Technologies Ltd. ("Hollysys" or the "Company") today issued a letter to shareho... |
| 30.01.2024 | Hollysys Reiterates Strong Support for Ascendent Deal; Provides Update on Engagement with Dazheng | - Special Committee concluded Dazheng proposal was not superior after rigorous negotiations
- Dazheng was unable to provide sufficient assurances around equity financing and last-minute introduction of yet another new member after multiple ... |
| 29.01.2024 | EDDIE MIDDLETON AND TIFFANY WONG OF ALVAREZ & MARSAL APPOINTED AS LIQUIDATORS OF CHINA EVERGRANDE GROUP (IN LIQUIDATION) | HONG KONG, Jan. 29, 2024 /PRNewswire/ -- By order of the High Court of Hong Kong, Mr. Edward Simon Middleton and Ms. Wing Sze Tiffany Wong, both Managing Directors of Alvarez & Marsal Asia Limited, have been appointed as joint and sever... |
| 11.01.2024 | HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status | — NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —
— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia w... |
| 10.01.2024 | Inventiva annonce le tirage de la seconde tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement | Inventiva utilisera le produit de ce tirage pour financer une partie de l'étude clinique pivot de Phase III en cours évaluant lanifibranor chez des patients atteints de la NASH.
Cette seconde tranche est assortie d'un taux d'intérêt de 7% p... |
| 10.01.2024 | Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank | Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH.
This second tranche carries an interest rate of 7% annually and has a maturity of 3 yea... |
| 09.01.2024 | Lotus Technology Showcases Autonomous Driving Progress at CES 2024 | NEW YORK and SINGAPORE, Jan. 9, 2024 /PRNewswire/ -- Lotus Technology Inc. ("Lotus Tech" or the "Company"), a leading global luxury electric vehicle maker, announced today that its intelligent driving arm, Lotus Robotics... |
| 05.01.2024 | Hollysys Announces Shareholder Meeting to Vote on Acquisition by Ascendent Capital Partners | -- Board recommends shareholders to vote "FOR" merger agreement for acquisition by Ascendent at $26.50/share
BEIJING, Jan. 5, 2024 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the &... |
